Relapsing polychondritis is a rare autoimmune disease in which the body’s immune system attacks its own cartilage, causing painful, recurring episodes of inflammation in the ears, nose, airways, joints, and other cartilage-rich structures. Because it can also strike the eyes, heart, and inner ear, the disease often looks like several different conditions at once, which helps explain why many people wait years before getting a correct diagnosis. The underlying driver appears to be an immune reaction against proteins found in cartilage, but the disease’s rarity has made it difficult to study in large numbers, and much of what clinicians know still comes from case series and small cohorts.
What Causes Relapsing Polychondritis
The short answer is that the immune system mistakes cartilage proteins for foreign invaders, but researchers are still piecing together exactly why this happens. The strongest evidence points to type II collagen, the main structural protein in cartilage, as a key target. In the late 1970s, antibodies specifically directed against type II collagen were found in the blood of patients during acute flares, and their levels seemed to track with how severe symptoms were.1PubMed. Antibodies to type II collagen in relapsing polychondritis Animal experiments reinforced this idea: when rats were immunized with type II collagen, they developed ear inflammation that closely mimicked the human disease.2PubMed Central. Auricular chondritis in rats. An experimental model of relapsing polychondritis induced with type II collagen
Type II collagen isn’t the only target, though. Some patients also produce antibodies against matrilin-1, a protein found mainly in the cartilage of the windpipe and airways. In one study, positive matrilin-1 antibody levels correlated with respiratory symptoms in about seven out of ten cases, which may help explain why some patients develop life-threatening airway problems while others do not.3Arthritis & Rheumatism. The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis Beyond these cartilage-specific proteins, broader immune activation involving T cells and inflammatory signaling molecules plays a role, but the precise chain of events that triggers the first flare remains unknown.
Genetic Susceptibility
Not everyone who has the relevant immune tendencies develops relapsing polychondritis, and genetics appear to be part of the explanation. One well-established association is with HLA-DR4, a gene variant involved in how the immune system recognizes threats. In one study, roughly 56% of patients with relapsing polychondritis carried the HLA-DR4 marker, compared with about 26% of healthy controls.4PubMed. Susceptibility to relapsing polychondritis is associated with HLA-DR4 A later genotyping study in a Japanese cohort identified additional susceptibility alleles and noted that the genetic profile of relapsing polychondritis was distinct from that of other autoimmune conditions like rheumatoid arthritis, even though both diseases share some HLA associations.5PubMed. Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases Having HLA-DR4 does not mean someone will develop the disease; it simply raises the baseline probability. No single gene or environmental trigger has been identified as the definitive cause.
How Symptoms Typically Appear
The hallmark of relapsing polychondritis is ear inflammation, and for good reason: it is the presenting feature in the majority of patients. In one analysis, inflammation of the outer ear was the initial sign in about 80% of cases.6PubMed Central. Relapsing polychondritis – analysis of symptoms and criteria The telltale pattern is redness, swelling, and tenderness of the cartilage-containing upper portion of the ear, while the fleshy earlobe, which has no cartilage, is spared. Repeated flares can eventually destroy the cartilage framework, leaving the ear floppy or deformed. A similar process can affect the nose: the cartilaginous bridge collapses over time, producing what clinicians call a “saddle nose” deformity.
Joint pain is another common complaint. The arthritis associated with relapsing polychondritis tends to be non-erosive, meaning it does not eat away at bone the way rheumatoid arthritis does, but it can still be quite painful. It may affect both large and small joints and can sometimes be the only symptom for months before cartilage inflammation appears elsewhere. The disease can involve elastic cartilage in the ears and nose, hyaline cartilage in peripheral joints, fibrocartilage at spinal sites, and the cartilage rings of the trachea and bronchi.7PubMed Central. Relapsing polychondritis: inflamed joints and ears
Airway Involvement and Why It Matters Most
The most dangerous complication of relapsing polychondritis is damage to the airways. When the cartilage rings supporting the trachea and bronchi weaken, the result can be tracheobronchomalacia, a condition in which the airways become floppy and prone to collapse during breathing. This can progress to laryngeal stenosis, where the upper airway narrows enough to cause choking.8Nature (Scientific Reports). Evaluation of airway involvement and treatment in patients with relapsing polychondritis Patients with airway involvement may notice a dry cough, hoarseness, shortness of breath, or a feeling of throat tightness well before the situation becomes critical. These symptoms deserve urgent attention, because once significant cartilage is lost, the structural damage is essentially permanent.
In severe or emergency situations, airway stenting can be lifesaving. Reports have described metallic stents dramatically improving severe airway obstruction when other options failed.9PubMed Central. Sudden Respiratory Failure due to Tracheobronchomalacia by Relapsing Polychondritis, Successfully Rescued by Multiple Metallic Stenting and Tracheostomy More recently, silicone Y-shaped stents combined with temporary extracorporeal membrane oxygenation have been used as salvage therapy for catastrophic tracheal injuries in patients with relapsing polychondritis.10PubMed Central. Relapsing polychondritis with catastrophic tracheal injury: extracorporeal membrane oxygenation and silicone Y-stenting for salvage therapy These are last-resort measures, but their existence highlights how dangerous airway disease can become.
Eye, Ear, and Cardiovascular Complications
Relapsing polychondritis frequently reaches beyond cartilage. In a series of patients followed at one center, 57 out of the total cohort developed eye symptoms over the course of the disease, and 21 had eye problems as their very first sign. Complications ranged from mild redness and irritation to serious conditions like scleritis, corneal thinning, and optic neuritis.11PubMed. Ocular and systemic findings in relapsing polychondritis Inner ear inflammation can cause hearing loss, dizziness, and balance problems; one large review estimated that hearing loss occurs in about a third of patients over time.12RMD Open. Relapsing polychondritis: state of the art on clinical practice guidelines
The cardiovascular system is another vulnerable target. Aortic regurgitation, where the aortic valve leaks, and aortic aneurysm are the most frequently reported heart-related problems. Cases of heart block and acute pericarditis have also been documented. Cardiovascular complications are considered the second most frequent cause of death in relapsing polychondritis, after respiratory causes.13PubMed Central. Cardiovascular involvement in relapsing polychondritis Because these complications can develop silently, periodic monitoring with imaging and cardiac evaluation is part of routine follow-up for anyone living with the disease.
Skin Manifestations
Skin problems in relapsing polychondritis are more common than many patients expect. In a study of 200 patients at a single center, about 35% of those without a co-existing skin disease developed dermatologic symptoms. The most frequent were mouth ulcers, nodules on the limbs, purpura, papules, and sterile pustules. Skin signs were actually the presenting feature of the disease in about 12% of cases, appearing before any recognizable cartilage inflammation.14PubMed Central. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center This is one of the reasons the condition is so often misdiagnosed early on: a patient whose first symptom is mouth sores or a leg rash is unlikely to be referred to a rheumatologist right away.
How Relapsing Polychondritis Is Diagnosed
There is no single blood test that confirms relapsing polychondritis. Diagnosis is primarily clinical, based on recognizing a pattern of recurring cartilage inflammation across multiple sites. Several sets of criteria have been proposed over the decades, and in one small analysis, nine out of ten patients with the disease met at least one established set of diagnostic criteria.6PubMed Central. Relapsing polychondritis – analysis of symptoms and criteria In practice, a rheumatologist looks for combinations like bilateral ear chondritis, nasal cartilage inflammation, airway involvement, audiovestibular damage, and non-erosive joint inflammation. A biopsy of inflamed cartilage showing characteristic destruction can support the diagnosis but is not always necessary if the clinical picture is clear enough.
Standard lab work tends to show nonspecific signs of inflammation: elevated inflammatory markers and sometimes anemia. Antibodies to type II collagen can be detected, but a recent prospective analysis found that their levels did not actually correlate with disease activity, which limits their usefulness for monitoring.15PubMed Central. Performance Characteristics of Anti-Collagen II Antibodies in Relapsing Polychondritis and Related Diseases: Prospective Analysis, Systematic Review, and Meta-Analysis This means a negative antibody test does not rule the disease out, and a positive test does not necessarily mean a flare is underway.
Imaging has become an increasingly valuable part of the workup. PET/CT scanning can identify areas of increased metabolic activity in cartilaginous structures throughout the body, even before physical changes are visible on physical exam. One case series demonstrated that PET/CT could accurately map the extent of inflammation in nasal, laryngeal, tracheobronchial, and rib cartilages, making it a useful tool for establishing the diagnosis and assessing how widespread the disease is.16PubMed. Relapsing polychondritis on PET/CT CT of the chest and bronchoscopy are commonly used to evaluate airway involvement directly.17PubMed Central. 18F-FDG PET/CT imaging of relapsing polychondritis
Treatment Strategy
Because relapsing polychondritis is so rare, there are no large randomized controlled trials to guide treatment. Management is based on accumulated clinical experience and small series, and it tends to follow a stepwise approach: start with the mildest effective therapy and escalate if the disease does not respond or if serious organs are threatened.
For mild disease, such as isolated ear or nasal inflammation without organ-threatening features, nonsteroidal anti-inflammatory drugs or low-dose corticosteroids may be enough to control flares. When flares are more severe or frequent, oral corticosteroids like prednisolone become the backbone of treatment. The problem is that long-term steroid use carries its own serious risks, so doctors typically try to add a steroid-sparing immunosuppressant. Methotrexate is probably the most commonly used agent in this role and has been reported to allow meaningful reductions in steroid dosing.18PubMed. Steroid sparing effect of methotrexate in relapsing polychondritis Other conventional immunosuppressants used include azathioprine, mycophenolate mofetil, and cyclophosphamide, with the last typically reserved for the most severe presentations such as systemic vasculitis or rapidly progressive airway disease.19PubMed Central. Relapsing polychondritis
Biologic Therapies
When conventional immunosuppressants are not enough, biologic agents are the next step. A French national study tracked 41 patients exposed to a total of 105 biologic drug courses and found an overall response rate of about 63% during the first six months, with a complete response in roughly 19%.20Annals of the Rheumatic Diseases. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study TNF-alpha inhibitors such as infliximab and adalimumab are the most commonly prescribed biologics for the disease, and many patients achieve at least partial improvement. However, loss of effectiveness over time has been observed, which sometimes necessitates switching to a different drug.21PubMed. Biologic therapy in relapsing polychondritis: navigating between options
When TNF inhibitors fail or lose their effect, tocilizumab and abatacept have been used as second-line biologic options with reported effectiveness. The evidence for anakinra and rituximab in relapsing polychondritis is more mixed, and these are generally not recommended as first-line biologic choices.21PubMed. Biologic therapy in relapsing polychondritis: navigating between options New targeted therapies, including JAK inhibitors, are being explored, but published data are limited to individual case reports at this point. The overall landscape is one of trial and error, with treatment plans heavily personalized to each patient’s disease pattern.
The VEXAS Connection
One of the most significant developments in relapsing polychondritis in recent years is the discovery that a meaningful subset of patients actually have a distinct genetic condition called VEXAS syndrome. VEXAS is caused by acquired mutations in a gene called UBA1, and more than half of patients identified with VEXAS meet diagnostic criteria for relapsing polychondritis, making the overlap substantial.22PubMed Central. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS In one cohort of 92 patients carrying a diagnosis of relapsing polychondritis, about 8% were found to harbor UBA1 mutations when tested.22PubMed Central. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS A Japanese study found even higher rates, with 73% of male patients in their relapsing polychondritis cohort testing positive for UBA1 variants.23Annals of the Rheumatic Diseases. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis
Distinguishing VEXAS-driven disease from “idiopathic” relapsing polychondritis matters because the two groups look different clinically and may need different management. Compared with patients who have conventional relapsing polychondritis, VEXAS patients are overwhelmingly male, tend to be older at diagnosis (a median age around 66 versus 44), and have much higher rates of fever, skin lesions, blood clots, and a blood disorder called myelodysplastic syndrome.24RMD Open. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients The practical takeaway is that any man diagnosed with relapsing polychondritis, especially if he is over 45 and has systemic symptoms like recurrent fevers and unexplained blood count abnormalities, should be screened for VEXAS. The distinction can change the treatment approach substantially, as VEXAS may ultimately require bone marrow transplantation rather than conventional immunosuppression.
Monitoring Disease Activity
Tracking how active the disease is at any given time remains a challenge. A scoring tool called the Relapsing Polychondritis Disease Activity Index (RPDAI) has been developed to standardize assessment. It accounts for the range of possible organ involvement over a 28-day period and gives clinicians a numerical measure of disease severity.25PubMed Central. Relapsing polychondritis: clinical presentations, disease activity and outcomes While the RPDAI has been used in research settings, there is still no universally adopted monitoring strategy. Routine follow-up typically combines regular physical examinations, inflammatory blood markers, pulmonary function testing, and periodic imaging depending on which organs are involved.
The lack of a reliable blood biomarker remains a frustration. As noted earlier, anti-collagen II antibody levels do not reliably reflect whether the disease is active. Clinicians end up relying heavily on patient-reported symptoms and serial imaging to judge whether treatment is working, which adds to the burden on patients who may already be seeing multiple specialists.
Living with Relapsing Polychondritis
The impact of relapsing polychondritis on daily life is substantial and often underestimated by people who focus only on the physical symptoms. A qualitative study focused on quality of life found that the disease disrupts nearly every aspect of a patient’s world. The domains most frequently affected were personal relationships, work capacity, and routine daily activities, and the researchers noted that social isolation, reduced productivity, and difficulty maintaining a normal life were common consequences.26PubMed Central. Identifying quality of life domains and facets affected in relapsing polychondritis: a qualitative analysis for the development of a disease-specific health-related quality of life instrument
Patient surveys reinforce the same picture. The unpredictable flare-relapse cycle makes it hard to plan ahead, and the variety of symptoms means patients often see many different specialists, none of whom may feel they “own” the condition. In a large patient-reported dataset, diagnostic delay and lack of standardized treatment were identified as major unmet needs.27PubMed Central. Patient Perception of Disease-Related Symptoms and Complications in Relapsing Polychondritis One review estimated that about a quarter of patients develop disability over time, and tracheomalacia occurs in roughly 16% of those with respiratory involvement.12RMD Open. Relapsing polychondritis: state of the art on clinical practice guidelines Coordinating care through a multidisciplinary team, ideally anchored by a rheumatologist with input from pulmonology, ENT, ophthalmology, and cardiology as needed, is widely recommended but not always easy to arrange in practice, especially for patients who live far from academic medical centers.
Why Diagnosis Takes So Long
One of the most consistent frustrations patients describe is the time it takes to get a correct diagnosis. This delay is partly structural: relapsing polychondritis is rare enough that many physicians will never see a case in their careers, so it often is not considered when a patient presents with isolated ear redness, a hoarse voice, or joint pain. The fact that early symptoms can mimic far more common conditions like ear infections, allergic reactions, rheumatoid arthritis, or granulomatosis with polyangiitis means patients frequently receive other diagnoses first. When dermatologic symptoms are the presenting feature, the path to a rheumatologist may be even longer. The mean age at diagnosis in one series was about 54, with a wide range from the early thirties to the seventies, suggesting that the disease can simmer for years before the clinical pattern becomes recognizable.6PubMed Central. Relapsing polychondritis – analysis of symptoms and criteria
Awareness campaigns and the growing availability of PET/CT scanning may eventually shorten this gap. In the meantime, patients who experience recurrent, unexplained inflammation in cartilaginous structures, particularly bilateral ear swelling that spares the lobes, should advocate for a rheumatology referral. Documenting flares with photographs and keeping a symptom diary can help, since relapsing polychondritis often declares itself over time rather than all at once.